Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™.
Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
https://botanixpharma.com/wp-content/uploads/Sharecafe-Matt-Callahan.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:55:372025-03-16 21:55:38Sharecafe | Interview with Matt Callahan
Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.
The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.
To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.
https://botanixpharma.com/wp-content/uploads/ASX-300.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:17:142025-03-16 21:17:44Botanix included in ASX 300 Index
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.
https://botanixpharma.com/wp-content/uploads/Copy-of-BOT-website-announcement-1-1.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-12-29 19:06:382024-12-29 19:06:39The West Australian: ‘Botanix ships first batch of sweat-stopper gel’
First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
Sharecafe | Interview with Matt Callahan
/in Featured, Latest News, News /by Haley ChartresBotanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™.
Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
Botanix included in ASX 300 Index
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.
The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.
To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.
Click here to see the ASX announcement
Euroz Hartleys Research Report
/in Featured, Latest News, News /by Haley ChartresEuroz Hartleys has published a research note on Botanix forecasting strong sales momentum for Sofdra™.
Click here to read the report.
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News, News /by Haley ChartresQuarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
The West Australian: ‘Botanix ships first batch of sweat-stopper gel’
/in Featured, Latest News, News /by Haley ChartresBotanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.
Read article
First Sofdra™ prescriptions as commercialization ramps up
/in ASX Releases, Featured, Latest News, News /by Haley ChartresFirst prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
View release.